The management of attention-deficit hyperactivity disorder in children: Updated 2019

N. Schellack, J. C. Meyer*, A. K. Chigome

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

Abstract

Attention-deficit hyperactivity disorder (ADHD) is a neurodevelopmental disorder and involves the academic, social and family functioning of the child. It is the most commonly diagnosed behavioural disorder amongst children with a prevalence of approximately 7.2% worldwide, occurring mostly in boys. The consequences of ADHD may be substance abuse and other personality disorders, e.g. delinquency. Research has indicated that drug or behavioural interventions may decrease the rate of conduct and personality disorders. Diet therapy may include polyunsaturated fatty acids (fish oil) and iron supplements in children with low ferritin levels which may improve ADHD symptoms. Drug therapy that involves stimulants (methylphenidate) has been proven to be effective with a good safety profile. However, concerns have been raised about cardiac, psychiatric and growth side-effects. The non-stimulants (atomoxetine) have no abuse potential and reduce insomnia. They also have a better effect on growth in children. Other therapies include antidepressants and α2-agonists. It is important to treat each patient using individualised therapy. The role of the pharmacist is important to monitor and minimise side-effects. New treatment options comprise modified formulations of currently available medicines.

Original languageEnglish
Pages (from-to)17-27
Number of pages11
JournalSA Pharmaceutical Journal
Volume86
Issue number5
Publication statusPublished - Dec 2019

Keywords

  • ADHD
  • Atomoxetine
  • Attention-deficit hyperactivity disorder
  • Children
  • Methylphenidate

Fingerprint

Dive into the research topics of 'The management of attention-deficit hyperactivity disorder in children: Updated 2019'. Together they form a unique fingerprint.

Cite this